Suppr超能文献

女性盆底医学与重建外科术后阿片类药物处方

Postoperative Opioid Prescribing After Female Pelvic Medicine and Reconstructive Surgery.

机构信息

From the Urogynecology and Pelvic Reconstructive Surgery, MultiCare Health Systems, Tacoma, WA.

Division of Urognecology, The Oregon Clinic, Portland, OR.

出版信息

Female Pelvic Med Reconstr Surg. 2021 Nov 1;27(11):643-653. doi: 10.1097/SPV.0000000000001113.

Abstract

OBJECTIVE

This study aimed to provide female pelvic medicine and reconstructive surgery (FPMRS) providers with evidence-based guidance on opioid prescribing following surgery.

METHODS

A literature search of English language publications between January 1, 2000, and March 31, 2021, was conducted. Search terms identified reports on opioid prescribing, perioperative opioid use, and postoperative pain after FPMRS procedures. Publications were screened, those meeting inclusion criteria were reviewed, and data were abstracted. Data regarding the primary objective included the oral morphine milligram equivalents of opioid prescribed and used after discharge. Information meeting criteria for the secondary objectives was collected, and qualitative data synthesis was performed to generate evidence-based practice guidelines for prescription of opioids after FPMRS procedures.

RESULTS

A total of 6,028 unique abstracts were identified, 452 were screened, and 198 full-text articles were assessed for eligibility. Fifteen articles informed the primary outcome, and 32 informed secondary outcomes.

CONCLUSIONS

For opioid-naive patients undergoing pelvic reconstructive surgery, we strongly recommend surgeons to provide no more than 15 tablets of opioids (roughly 112.5 morphine milligram equivalents) on hospital discharge. In cases where patients use no or little opioids in the hospital, patients may be safely discharged without postoperative opioids. Second, patient and surgical factors that may have an impact on opioid use should be assessed before surgery. Third, enhanced recovery pathways should be used to improve perioperative care, optimize pain control, and minimize opioid use. Fourth, systemic issues that lead to opioid overprescribing should be addressed. Female pelvic medicine and reconstructive surgery surgeons must aim to balance adequate postoperative pain control with individual and societal risks associated with excess opioid prescribing.

摘要

目的

本研究旨在为女性盆底医学和重建外科(FPMRS)提供者提供手术后开具阿片类药物的循证指导。

方法

对 2000 年 1 月 1 日至 2021 年 3 月 31 日期间发表的英文文献进行了检索。检索词确定了关于阿片类药物处方、围手术期阿片类药物使用以及 FPMRS 手术后疼痛的报告。对出版物进行筛选,对符合纳入标准的出版物进行了审查,并提取了数据。与主要目标相关的数据包括出院后开出和使用的口服吗啡毫克当量。收集符合次要目标标准的信息,并进行定性数据综合,以生成 FPMRS 手术后开具阿片类药物的循证实践指南。

结果

共确定了 6028 篇独特的摘要,筛选了 452 篇,评估了 198 篇全文文章的资格。15 篇文章为主要结果提供了信息,32 篇文章为次要结果提供了信息。

结论

对于接受盆底重建手术的阿片类药物初治患者,我们强烈建议外科医生在出院时提供不超过 15 片阿片类药物(约 112.5 毫克吗啡当量)。如果患者在医院中不使用或很少使用阿片类药物,则可以安全地不使用术后阿片类药物出院。其次,应在手术前评估可能影响阿片类药物使用的患者和手术因素。第三,应使用强化康复途径来改善围手术期护理,优化疼痛控制并减少阿片类药物的使用。第四,应解决导致阿片类药物过度处方的系统性问题。女性盆底医学和重建外科医生必须旨在平衡术后疼痛控制与过度开具阿片类药物相关的个体和社会风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验